» Articles » PMID: 31691197

Anti-HER2 ScFv Expression in Escherichia Coli SHuffleT7 Express Cells: Effects on Solubility and Biological Activity

Overview
Journal Mol Biotechnol
Publisher Springer
Date 2019 Nov 7
PMID 31691197
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is the second most commonly diagnosed cancer, worldwide. Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer is correlated with poor prognosis. HER2-targeting monoclonal antibodies resulted in longer survival of HER2 breast cancer. Single-chain variable fragment (scFv) demonstrates improved penetrability into tumors. Due to the presence of two disulfide bond, scFv expression in reducing bacterial cytoplasm may cause formation of inclusion bodies. Disulfide bond can be formed properly in cytoplasm of SHuffle strain as it is trxB, gor, and overexpresses cytoplasmic DsbC chaperone. In this study, the anti-HER2 scFv was successfully expressed and purified in BL21 (DE3) and SHuffle cells. Here, significant higher soluble anti-HER2 scFv was produced in SHuffle than in BL21 strain. The specific binding of anti-HER2 scFv to HER2 was shown by flow cytometry analysis and ELISA. Moreover, it was demonstrated that the anti-HER2 scFv produced in SHuffle binds to HER2 at higher level as compared to that expressed in BL21 cells. Furthermore, competitive ELISA-based study suggested that anti-HER2 scFv recognizes the same epitope of HER2 receptor as the trastuzumab antibody. Our findings indicated that correct disulfide bond formation in SHuffle strain can result in enhanced solubility and higher biological activity level of anti-HER2 scFv.

Citing Articles

Expression of thermostable MMLV reverse transcriptase in Escherichia coli by directed mutation.

Divbandi M, Yamchi A, Nikoo H, Moradi A, Tabarraei A AMB Express. 2024; 14(1):113.

PMID: 39363125 PMC: 11450115. DOI: 10.1186/s13568-024-01773-6.


Integrated bioprocessing and genetic strategies to enhance soluble expression of anti-HER2 immunotoxin in E. Coli.

Mani S, Arab B, Akbari V, Chou C AMB Express. 2024; 14(1):107.

PMID: 39341967 PMC: 11438746. DOI: 10.1186/s13568-024-01765-6.


The Potential of Single-Chain Variable Fragment Antibody: Role in Future Therapeutic and Diagnostic Biologics.

Gezehagn Kussia G, Tessema T J Immunol Res. 2024; 2024:1804038.

PMID: 39156005 PMC: 11329312. DOI: 10.1155/2024/1804038.


Scalable, robust, high-throughput expression & purification of nanobodies enabled by 2-stage dynamic control.

Hennigan J, Menacho-Melgar R, Sarkar P, Golovsky M, Lynch M Metab Eng. 2024; 85:116-130.

PMID: 39059674 PMC: 11408108. DOI: 10.1016/j.ymben.2024.07.012.


Cytoplasmic Expression of Disulfide-Bonded Proteins: Side-by-Side Comparison between Two Competing Strategies.

Castillo-Corujo A, Uchida Y, Saaranen M, Ruddock L J Microbiol Biotechnol. 2024; 34(5):1126-1134.

PMID: 38563095 PMC: 11180911. DOI: 10.4014/jmb.2311.11025.


References
1.
Lauber J, Handrick R, Leptihn S, Durre P, Gaisser S . Expression of the functional recombinant human glycosyltransferase GalNAcT2 in Escherichia coli. Microb Cell Fact. 2015; 14:3. PMC: 4299809. DOI: 10.1186/s12934-014-0186-0. View

2.
Spigel D, Burstein H . HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol. 2002; 3(2):163-74. DOI: 10.1007/s11864-002-0062-8. View

3.
Cao Y, Marks J, Huang Q, Rudnick S, Xiong C, Hittelman W . Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2011; 11(1):143-53. DOI: 10.1158/1535-7163.MCT-11-0519. View

4.
de Marco A . Strategies for successful recombinant expression of disulfide bond-dependent proteins in Escherichia coli. Microb Cell Fact. 2009; 8:26. PMC: 2689190. DOI: 10.1186/1475-2859-8-26. View

5.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View